These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22954756)

  • 1. Telaprevir: pharmacokinetics and drug interactions.
    Garg V; Kauffman RS; Beaumont M; van Heeswijk RP
    Antivir Ther; 2012; 17(7):1211-21. PubMed ID: 22954756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir.
    Prescrire Int; 2012 Apr; 21(126):93-6. PubMed ID: 22515133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical and pharmacological features of telaprevir].
    Andrade RJ; García-Samaniego J
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():2-6. PubMed ID: 24063896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
    Klibanov OM; Williams SH; Smith LS; Olin JL; Vickery SB
    Pharmacotherapy; 2011 Oct; 31(10):951-74. PubMed ID: 21950642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
    Nehra V; Rizza SA; Talwani R; Temesgen Z
    Drugs Today (Barc); 2011 Nov; 47(11):829-37. PubMed ID: 22146226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
    Milazzo L; Falvella FS; Magni C; Gervasoni C; Peri AM; Cattaneo D; Antinori S; Vidale S
    Pharmacology; 2013; 92(5-6):235-7. PubMed ID: 24192929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of drug interactions with telaprevir and antiretrovirals.
    van Heeswijk RP; Beumont M; Kauffman RS; Garg V
    Antivir Ther; 2013; 18(4):553-60. PubMed ID: 23344266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
    Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S
    Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic interactions of telaprevir with other drugs].
    Berenguer Berenguer J; González-García J
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():37-48. PubMed ID: 24063902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Telaprevir-induced pityriasis rubra pilaris].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
    [No Abstract]   [Full Text] [Related]  

  • 17. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.
    Kiang TK; Wilby KJ; Ensom MH
    Clin Pharmacokinet; 2013 Jul; 52(7):487-510. PubMed ID: 23553423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.
    Smith LS; Nelson M; Naik S; Woten J
    Ann Pharmacother; 2011 May; 45(5):639-48. PubMed ID: 21558488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.
    Monteagudo E; Fonsi M; Chu X; Bleasby K; Evers R; Pucci V; Orsale MV; Cianetti S; Ferrara M; Harper S; Laufer R; Rowley M; Summa V
    Xenobiotica; 2010 Dec; 40(12):826-39. PubMed ID: 20925584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.